Pfizer-BioNTech Cutting Back Vaccine Deliveries to Canada Due to Production Issues

January 15, 2021 Updated: January 15, 2021

OTTAWA—Procurement Minister Anita Anand says production issues in Europe will temporarily reduce Pfizer-BioNTech’s ability to deliver vaccines to Canada.

Anand says the U.S. drug-maker is temporarily reducing deliveries because of issues with its European production lines.

She adds that while the company says it will still be able to deliver four million doses by the end of March, that is no longer guaranteed.

“This is unfortunate. However such delays and issues are to be expected when global supply chains are stretched well beyond their limits,” Anand said at a news conference Friday. “It’s not a stoppage.”

Canada has received about 380,000 doses of the vaccine so far, and was supposed to get another 400,000 this month and almost two million doses in February.

The news comes as Ottawa released federal projections that suggest the pandemic may soon exceed levels seen in the first wave, rising to 19,630 cumulative deaths by Jan. 24.

Chief Public Health Officer Dr. Theresa Tam urged sustained vigilance as a long-range forecast suggested rapid growth in infections will continue without “quick, strong and sustained” measures.

Tam says that’s especially so in the national hot spots of Quebec and Ontario, where a steady increase in hospitalizations has strained the health system’s ability to keep up with critical care demands.